Clinical Diversity and Genetic Variation in Lysosomal Disorders

Scroll to the bottom of this page to obtain CME/CE credit

Lysosomal & Rare Disorders Research & Treatment Center

GRIDS-2021

Clinical Diversity and Genetic Variation in Lysosomal Disorders

July 16, 2021 – July 15, 2022

NO LONGER AVAILABLE FOR CREDIT

Continuing Education Information

This continuing education activity is provided through collaboration between Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for Physicians, Physician Assistants, Nurses, Nurse Practitioners, Genetic Counselors as well as a statement of participation for other attendees.

Faculty

Ozlem Goker-Alpan, MD
Founder and President
Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)

Gregory Grabowski, MD
Department of Pediatrics
University of Cincinnati College of Medicine
Division of Human Genetics

Soumeya Bekri, MD, PhD
Rouen University Hospital, France

Learning Outcomes

At the end of this activity, participants should be able to:

  • Explain the principles of Pathogenic Processes in LSDs.
  • Explain that lysosomal composition, shape, contents, numbers differ between cell types
    and have an effect on disease expression.
  • Review the evolving understanding of lysosomal autophagy functions.

Disclosures

AffinityCE staff, LDRTC staff, planning and review committees have no financial interests to disclose and do not recommend the use of products outside of the FDA approved labelling.

Faculty disclosures

Ozlem Goker-Alpan, MD
BioEvents: Speaker
Cheisi, Sanofi Genzyme, Takeda, Amicus, Prevail, Freeline: Consultant
Chiesi, Takeda, Sanofi Genzyme, Amicus, Avrobio, Idorsia, 4DMT, Sangamo, Protalix: Grant PI
Cheisi, Takeda, Sanofi Genzyme, Amicus, Avrobio, Idorsia, 4DMT, Sangamo, Protalix, Prevail Therapeutics: Consultant
Takeda, Sanofi Genzyme, Pfizer, Centogene: Grants

Gregory Grabowski, MD
Asklepios Biotherapeutics–: Clinical SAB 2018, SAB 2020-
Sanofi Genzyme: Consultant 1989-2013, 2020
Lysosomal Therapeutics, Inc.: SAB 2015-2017, Consultant 2018, 2019
Prevail Therapeutics: Consultant 2017-2021
RallyBio, Inc: Consultant, 2020

Soumeya Bekri, MD, PhD
Sanofi Genzyme, Takeda, Biomarin, Amicus, Alexion, Ultragenyx, PerkinElmer, Thermo Fisher: Grants/ Research Support

Conflict of interest for Dr. Goker-Alpan and Dr. Grabowski and Prof. Bekri was resolved through peer review of content by a non-conflicted reviewer.

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 2 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 2 hours of continuing nursing education credit.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 2 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Genetic Counselors
Category 2 CEU

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 2 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.

Other Professionals

All other health care professionals completing this continuing education activity will be issued a Statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Commercial Support

Educational Support for this activity was provided by Takeda Pharmaceuticals USA, Inc., Genzyme Corporation, Spark Therapeutics, Inc., CHIESI USA, Inc., Amicus Therapeutics, Inc., Pfizer Inc., Ultragenyx Pharmaceutical, Inc., and AVROBIO, Inc.

Participation Costs

There is no cost to participate in these CE sessions.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.
Send customer support requests to cds_support+ldrtc@affinityced.com.